3 months ago
1
India’s cause regulator has inspected astir 90% of the country’s cough syrup makers and recovered compliance lapses, its chief said connected Monday (January 23, 2026), amid heightened scrutiny aft India-made syrups were linked to the deaths of children successful the state and abroad.
The inspections travel the find of a marque of cough syrup contaminated with diethylene glycol that was linked to the deaths of 24 children successful October last year. The product, named Coldrif, was made by Sresan Pharmaceutical, based in Tamil Nadu.
“We took superior actions connected superior non-compliances, and our content is that the rot of cough syrup manufacturing volition beryllium removed,” Drugs Controller General of India Rajeev Raghuvanshi said astatine the IPA 11th Global Pharmaceutical Quality Summit in Mumbai.
The regulator is looking to fix issues astir cough syrup products, helium said, without providing a timeline.
The bureau is nether unit to tighten oversight of the $42 cardinal pharma industry, dominated by tiny manufacturers, aft India-made cough syrups person been tied to the deaths of much than 140 children successful Africa and Central Asia since 2022, denting its estimation arsenic the “pharmacy of the world”.
About 90% of each cough syrup makers, around 1,100, had been inspected, Mr. Raghuvanshi said, and pointed to breaches of bully manufacturing practices, nonaccomplishment to trial incoming earthy materials and usage of invalid methods or processes. He did not sanction the companies recovered non-compliant.
The regulator has besides inspected an further 1,250 cause manufacturing units protectively to measure risks, a signifier begun successful 2022, helium said, but declined to accidental however galore had compliance issues oregon were forced to halt operations temporarily.
Regulator targets FDA-level standards
India’s cause regulator aims to bring its operations connected par with the U.S. Food and Drug Administration by addressing staffing shortages, speeding up approvals, and boosting resources, Mr. Raghuvanshi said.
The bureau plans to make 1,500 positions, with astir 40% of them flexible, declaration roles, and may bring successful planetary manufacture experts arsenic advisers. It is besides piloting the use of artificial quality to reappraisal applications, according to Mr. Raghuvanshi.
Separately, the regulator has streamlined export clearances by removing the request for alleged no-objection certificates for drugs shipped to the U.S., Europe, Australia, Japan, the UK and Canada, a determination helium said volition prevention clip and resources.
